MParks_IR

Vice President of #Investor Relations and #PublicRelations. Comments are my own.

[Defiant L’s @DefiantLs]

You haven't seen this one before

[MParks_IR @MParks_IR]

#1 @_CeeDeeThree and #CowboysNation fan ready for Gametime in the heart of #Philadelphia. Go @dallascowboys!.

[MParks_IR @MParks_IR]

$ATOS makes progress on #metastatic #BreastCancer! #smallcap #innovation https://t.co/CTIEbidH2A

[MParks_IR @MParks_IR]

@bullishbruk @quay_dr Thanks @bullishbruk!

[MParks_IR @MParks_IR]

@bullishbruk @quay_dr Reach out anytime. You have my contact info and I look forward to hearing from you. MP

[MParks_IR @MParks_IR]

@jbods211 @atossainc @quay_dr No spin needed. Please reach out to me directly for a response. My email and number are widely available, but please DM me if you can't find it. MP

[Atossa Therapeutics @atossainc]

More in today's news: (Z)-endoxifen at 10mg 1x daily met primary endpoint w/ 19/20 (95%) receiving >75% of planned treatment in I-SPY-2 Ph 2 Trial; Low dose (Z)-endoxifen was well tolerated and demonstrated promising rapid activity in reducing 3-wk Ki-67 & FTV Biomarkers $ATOS

[MParks_IR @MParks_IR]

Highly recommend signing up for @MaximGrp for $ATOS updates and other research.

[Maxim Group LLC @MaximGrp]

Please email: [email protected]

To receive: Maxim Group - Morning Minutes / Maxim Group - Equity Research

Atossa Therapeutics, Inc.
$ATOS

Please visit https://t.co/7l4XGN7ZeC for important disclosures.

[Atossa Therapeutics @atossainc]

More from Dr. Quay in today's announcement - Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- #BreastCancer https://t.co/WZSZxpYsWW

[MParks_IR @MParks_IR]

$ATOS

[Atossa Therapeutics @atossainc]

Did you know: Every 2 minutes an American woman is diagnosed with #breastcancer. Learn more about the #BreastCancerProblem & our mission -to develop innovative medicines to transform the cancer paradigm #BreastCancerAwarenessMonth https://t.co/VW467OWC0f

[Atossa Therapeutics @atossainc]

More from today's announcement - #breastcancer $ATOS https://t.co/JNWQuVGvhY

[Atossa Therapeutics @atossainc]

Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer - #breastcancer #biotech #fireside #collaboration @karolinskainst & @atossainc https://t.co/JNWQuVFXsq

[Forest @TraderForest]

$ATOS 💎💎💎

[MParks_IR @MParks_IR]

@bullishbruk @quay_dr Thank you! I always appreciate the feedback. @quay_dr and the team at $ATOS are outstanding and, as I hope you saw today, I am very happy to be here! Thanks again.

[Atossa Therapeutics @atossainc]

#BreastCancerAwarenessMonth #BreastCancer #BreastDensity

[Atossa Therapeutics @atossainc]

Check out the latest research from $ATOS - Comparative analysis of Endoxifen, Tamoxifen and Fulvestrant: A Bioinformatics Approach to Uncover Mechanisms of Action in #BreastCancer #research #biotech

https://t.co/otHfjOyLGB

[DenseBreast-Info.org @DenseBreastInfo]

JUST OUT: @AmericanCancer's Breast Cancer Facts & Figures 2024-2025. Did you know having extremely dense breasts is the same level of risk as having “2 or more first degree relatives with breast cancer”? See table 3 & Get Smart About Being Dense: https://t.co/uBuoh3Z7JV

[MParks_IR @MParks_IR]

@bullishbruk @quay_dr @atossainc @bullishbruk Thanks for the feedback and long-term interest! The $ATOS team is incredible - very happy to be here.

[Atossa Therapeutics @atossainc]

Did you know 50% of women worldwide have #DenseBreast tissue? Learn more about the Karisma Endoxifen Trial - investigating (Z)-endoxifen in premenopausal women with measurable mammographic breast density (MBD) #BreastCancer #BreastCancerAwareness $ATOS https://t.co/2x99PKnRki